Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease
progression leads to joint deformity and associated loss of function, which significantly …

Psoriasis is an immune-mediated disease, with the interleukin (IL)-23/IL-17 axis currently
considered its main pathogenic pathway. Tyrosine kinase 2 (TYK2) is responsible for …

Small molecule JAK inhibitors have emerged as a major therapeutic advancement in
treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that …

Psoriasis is a common inflammatory skin disease involving interactions between
keratinocytes and immune cells that significantly affects the quality of life. It is characterized …

TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines
have been implicated in the pathogenesis of multiple inflammatory and autoimmune …

Psoriasis is a prevalent chronic inflammatory disease. The inflammatory response is driven
by T cells and mediated by multiple cytokines such as tumor necrosis factor and the …

Janus kinase (JAK) inhibitors are novel treatment approaches for psoriasis. However, there
is no direct comparison of JAK inhibitors in plaque psoriasis. In order to compare the efficacy …

The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate
the intracellular signaling of cytokines in a wide spectrum of cellular processes. They …

Janus kinases (JAKs) mediate signal transduction downstream of cytokine receptors.
Cytokine-dependent dimerization is conveyed across the cell membrane to drive JAK …

Type I interferons (IFNs), mostly IFNα and IFNβ, and the type I IFN Signature are important in
the pathogenesis of Systemic Lupus Erythematosus (SLE), an autoimmune chronic …